Annaliesa Anderson, Pfizers senior vice president and head of vaccine research and development, touted the benefits of Penbrayawhich combines components from two other meningococcal vaccines, Trumenba and Nimenrixsaying the new vaccine has the potential to protect more adolescents and young adults from this severe and unpredictable disease by providing the broadest meningococcal coverage in the fewest shots. Approval for Penbraya was granted based on positive results from Phase II and III trials, including a Phase III study that sought to determine the immunologic noninferiority of the vaccine against meningococcal vaccines currently available in the U.S
Aliment Pharmacol Ther 36(4):379390 Szarka LA, Camilleri M (2009) Methods for measurement of gastric motility
What Is the Typical Timeline for Semaglutide Treatment
Additionally, such studies directly influence clinical practice, guiding healthcare providers in making evidence-based decisions in their daily patient care
DF, JB, and AS contributed the reagents, materials, and analysis tools
The graph shows the key stages and impacts associated with its development, along with annotations for each major milestone
